ProQR Therapeutics Stock Forecast

Stock Price Forecast

According to 8 analysts polled by S&P Global, ProQR Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $8.88. The average 1-year stock price forecast is 492.00% higher than the current stock price, while the lowest is $4.00 (+166.67%) and the highest is $14 (+833.33%).

Price Target: $8.88 (+492.00%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$4.00	$8.88	$8.50	$14
Change	+166.67%	+492.00%	+466.67%	+833.33%

Analyst Ratings

The average analyst rating for ProQR Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	7	7	7	7	7	7
Buy	1	1	1	1	1	1
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	8	8	8	8	8	8

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Ananda Ghosh H.C. Wainwright	H.C. Wainwright	Buy Reiterates $12	Buy	Reiterates	$12	+700.00%	May 13, 2026
Keay Nakae Chardan Capital	Chardan Capital	Buy Reiterates $4	Buy	Reiterates	$4	+166.67%	May 13, 2026
Steven Seedhouse Cantor Fitzgerald	Cantor Fitzgerald	Buy Maintains $8	Buy	Maintains	$8	+433.33%	Apr 15, 2026
Kostas Biliouris Oppenheimer	Oppenheimer	Buy Reiterates $9	Buy	Reiterates	$9	+500.00%	Apr 9, 2026
Jonathan Wolleben Citizens JMP	Citizens JMP	Buy Reiterates $8	Buy	Reiterates	$8	+433.33%	Mar 12, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

13.45M

from 16.35M

-17.73%

from 16.35M

Revenue Next Year

14.35M

from 13.45M

6.70%

from 13.45M

EPS This Year

-0.53

from -

EPS Next Year

-0.59

from -0.53

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	2.38M	4.36M	6.59M	19.55M	16.35M	13.45M
Revenue Growth	131.10%	83.30%	51.27%	196.41%	-16.36%	-17.73%
Gross Profit	2.38M	4.36M	6.59M	19.55M	16.35M	13.45M
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Income	-57.21M	-65.16M	-34.79M	-30.47M	-43.45M	-58.66M
Net Income	-60.74M	-64.42M	-28.12M	-27.76M	-42.18M	-57.82M
EPS	-	-	-	-	-	-0.53
Free Cash Flow	-16.21M	-99.16M	62.80M	-18.04M	-32.04M	-61.70M
No. Analysts	-	-	-	-	-	6

EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EUR.

Revenue Forecast

Revenue	2026	2027	2028
High	17.8M
Avg	13.4M
Low	2.0M

Revenue Growth

Revenue Growth	2026	2027	2028
High	8.9%
Avg	-17.7%
Low	-87.8%

EPS Forecast

EPS	2026	2027	2028
High	-
Avg	-0.53
Low	-

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-